Ran You
Principal Scientist – Oncology Research Amgen
Ran You, Ph.D., is a Principal Scientist in Oncology Discovery Research at Amgen with deep expertise in tumor immunology and mechanisms of response and resistance of T cell-directed immunotherapies. At Amgen, Dr. You has played a key role in supporting clinical-stage T cell engager programs for small cell lung cancer, including extensive preclinical work on tarlatamab, a DLL3-targeting bispecific T cell engager. Her research has elucidated how chemotherapy and immune checkpoint
blockade modulate tarlatamab activity, as well as biological drivers of efficacy and resistance. She also pioneered intravital imaging approaches to define spatial and cellular barriers to TCE efficacy in solid tumors. Dr. You has published widely in leading journals including Nature, Cancer Immunology Research, JCI, and Science Advances.
Seminars
- Tracing the breakthrough journey of tarlatamab from discovery to development, showcasing the scientific insights that enabled a first‑in‑class T‑cell–engager approach for SCLC
- Revealing the synergistic potential of pairing T‑cell engager molecules with checkpoint inhibitors and chemotherapy, supported by compelling preclinical evidence that demonstrates enhanced anti‑tumour activity and immune activation
- Highlighting emerging clinical data on tarlatamab and chemo‑immunotherapy combinations, illustrating how this strategy may unlock deeper, more durable responses for patients with limited treatment options
